98 related articles for article (PubMed ID: 8920773)
1. Mobilisation of blood progenitor cells with ifosfamide and etoposide (VP-16) in combination with recombinant human G-CSF (Filgrastim) in patients with malignant lymphomas or solid tumours.
Baars JW; Holtkamp MJ; Nooyen WJ; Walll EV; Te Velde A; Dalesio O; Slaper-Cortenbach IC; Schoot EV; Richel DJ; Gerritsen WR; Schornagel JH; Rodenhuis S
Anticancer Res; 1996; 16(5B):3089-95. PubMed ID: 8920773
[TBL] [Abstract][Full Text] [Related]
2. Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumor and non-Hodgkin's lymphoma patients after combination chemotherapy and G-CSF.
Engelhardt M; Winkler J; Waller C; Lange W; Mertelsmann R; Henschler R
Bone Marrow Transplant; 1997 Mar; 19(6):529-37. PubMed ID: 9181898
[TBL] [Abstract][Full Text] [Related]
3. Efficient peripheral blood stem cell mobilization with low-dose G-CSF (50 microg/m2) after salvage chemotherapy for lymphoma.
Martínez C; Sureda A; Martino R; Cancelas JA; Madoz P; García J; Brunet S
Bone Marrow Transplant; 1997 Nov; 20(10):855-8. PubMed ID: 9404926
[TBL] [Abstract][Full Text] [Related]
4. Combination chemotherapy containing mitoguazone, ifosfamide, methotrexate, etoposide (MIME) and G-CSF efficiently mobilize peripheral blood progenitor cells in heavily pre-treated relapsed lymphoma patients.
Aurlien E; Holte H; Kvaløy S; Jakobsen E; Rusten LS; Kvalheim G
Eur J Haematol Suppl; 2001 Jul; 64():14-20. PubMed ID: 11486395
[TBL] [Abstract][Full Text] [Related]
5. Ifosfamide- and etoposide-based chemotherapy as salvage and mobilizing regimens for poor prognosis lymphoma.
Mayer J; Vásová I; Korístek Z; Navrátil M; Klabusay M; Doubek M; Vorlícek J; Cernilová I; Vodvárka P; Petráková K
Eur J Haematol Suppl; 2001 Jul; 64():21-7. PubMed ID: 11486396
[TBL] [Abstract][Full Text] [Related]
6. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
Weaver CH; Schulman KA; Buckner CD
Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
[TBL] [Abstract][Full Text] [Related]
7. A randomised, blinded, placebo-controlled, dose escalation study of the tolerability and efficacy of filgrastim for haemopoietic stem cell mobilisation in patients with severe active rheumatoid arthritis.
Snowden JA; Biggs JC; Milliken ST; Fuller A; Staniforth D; Passuello F; Renwick J; Brooks PM
Bone Marrow Transplant; 1998 Dec; 22(11):1035-41. PubMed ID: 9877264
[TBL] [Abstract][Full Text] [Related]
8. A Phase I study of granulocyte-macrophage-colony stimulating factor/interleukin-3 fusion protein (PIXY321) following ifosfamide, carboplatin, and etoposide therapy for children with recurrent or refractory solid tumors: a report of the Children's Cancer Group.
Cairo MS; Krailo MD; Weinthal JA; Secola R; Bergeron S; van de Ven C; Blazar BR; Garrison L; Reaman GH
Cancer; 1998 Oct; 83(7):1449-60. PubMed ID: 9762948
[TBL] [Abstract][Full Text] [Related]
9. Peripheral blood progenitor cell transplantation: a single centre experience comparing two mobilisation regimens in 67 patients.
Mahendra P; Johnson D; Scott MA; Jestice HK; Hood IM; Ager S; Bass G; Barker P; Boraks PA; Bloxham DM; Baglin TP; Marcus RE
Bone Marrow Transplant; 1996 Apr; 17(4):503-7. PubMed ID: 8722346
[TBL] [Abstract][Full Text] [Related]
10. Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.
Damon L; Rugo H; Tolaney S; Navarro W; Martin T; Ries C; Case D; Ault K; Linker C
Biol Blood Marrow Transplant; 2006 Mar; 12(3):316-24. PubMed ID: 16503501
[TBL] [Abstract][Full Text] [Related]
11. A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy.
Russell N; Mesters R; Schubert J; Boogaerts M; Johnsen HE; Canizo CD; Baker N; Barker P; Skacel T; Schmitz N
Haematologica; 2008 Mar; 93(3):405-12. PubMed ID: 18268285
[TBL] [Abstract][Full Text] [Related]
12. Rituximab and ifosfamide, mitoxantrone, etoposide (RIME) with Neupogen support for B-cell non-Hodgkin's lymphoma prior to high-dose chemotherapy with autologous haematopoietic transplant.
Joyce RM; Kraser CN; Tetrealt JC; Giallombardo N; McDermott D; Levine J; Umiel T; Regan M; Hurley D; Uhl L; Avigan D
Eur J Haematol Suppl; 2001 Jul; 64():56-62. PubMed ID: 11486404
[TBL] [Abstract][Full Text] [Related]
13. EPO in combination with G-CSF improves mobilization effectiveness after chemotherapy with ifosfamide, epirubicin and etoposide and reduces costs during mobilization and transplantation of autologous hematopoietic progenitor cells.
Hart C; Grassinger J; Andreesen R; Hennemann B
Bone Marrow Transplant; 2009 Feb; 43(3):197-206. PubMed ID: 18806833
[TBL] [Abstract][Full Text] [Related]
14. CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients.
Todisco E; Castagna L; Sarina B; Mazza R; Magagnoli M; Balzarotti M; Nozza A; Siracusano L; Timofeeva I; Anastasia A; Demarco M; Santoro A
Eur J Haematol; 2007 Feb; 78(2):111-6. PubMed ID: 17313558
[TBL] [Abstract][Full Text] [Related]
15. Mobilisation of peripheral blood stem cells with IVE and G-CSF improves CD34+ cell yields and engraftment in patients with non-Hodgkin's lymphomas and Hodgkin's disease.
McQuaker I; Haynes A; Stainer C; Byrne J; Russell N
Bone Marrow Transplant; 1999 Oct; 24(7):715-22. PubMed ID: 10516673
[TBL] [Abstract][Full Text] [Related]
16. Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma.
Aurlien E; Holte H; Pharo A; Kvaløy S; Jakobsen E; Smeland EB; Kvalheim G
Bone Marrow Transplant; 1998 May; 21(9):873-8. PubMed ID: 9613778
[TBL] [Abstract][Full Text] [Related]
17. Peripheral blood progenitor cell collections in cancer patients: analysis of factors affecting the yields.
Sautois B; Fraipont V; Baudoux E; Fassotte MF; Hermanne JP; Jérusalem G; Bours V; Bosquée L; Schaaf-Lafontaine N; Paulus JM; Sondag D; Fillet G; Beguin Y
Haematologica; 1999 Apr; 84(4):342-9. PubMed ID: 10190949
[TBL] [Abstract][Full Text] [Related]
18. Feasibility of high-dose chemotherapy and autologous peripheral blood stem cell transplantation in children with high grade osteosarcoma.
Miniero R; Brach del Prever A; Vassallo E; Nesi F; Busca A; Fagioli F; Albiani R; Picci P; Bacci G; Madon E
Bone Marrow Transplant; 1998 Dec; 22 Suppl 5():S37-40. PubMed ID: 9989888
[TBL] [Abstract][Full Text] [Related]
19. Mobilization kinetics of peripheral blood progenitor cells after IAPVP-16 salvage chemotherapy plus G-CSF in lymphoproliferative disorders.
Altés A; López R; Martino R; Martinez C; Cabezudo E; Muñoz L; Santamaría A; Perea G; Briones J; Salar A; Sureda A; Brunet S; Madoz P; Sierra J
Bone Marrow Transplant; 2000 Jul; 26(2):127-32. PubMed ID: 10918421
[TBL] [Abstract][Full Text] [Related]
20. Mobilization of peripheral blood progenitor cells by high-dose Ara C, VP-16 and recombinant human granulocyte colony-stimulating factor: factors affecting progenitor cell yields.
Shimazaki C; Yamagata N; Tatsumi T; Hirata T; Oku N; Ashihara E; Goto H; Inaba T; Fujita N; Haruyama H
Bone Marrow Transplant; 1995 May; 15(5):763-7. PubMed ID: 7545490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]